Overview

Safety and Efficacy of a Monoclonal Antibody for Treatment of Rheumatoid Arthritis.

Status:
Completed
Trial end date:
2003-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether a humanized monoclonal antibody (efalizumab) is safe and effective in the treatment of rheumatoid arthritis.
Phase:
Phase 2
Details
Lead Sponsor:
XOMA (US) LLC